Novartis multiple sclerosis Class 1 new drug Sinimod tablets approved for listing in China

REVIEW: Orphan "multiple sclerosis" of new drugs coming!According to Chi medicine has learned that May 11, the State Food and Drug Administration announced approval of a Class 1 drug innovation Fuad Maude declared by Novartis Pharma AG priority review approval process film (trade name: Wan Li energy) market, for the treatment of adults with relapsing forms of multiple sclerosisSydney Maude is a receptor sphingosine-1-phosphate (S1P) modulators, S1P receptor subtype selectivity 1 (S1P1) and subtype 5 (S1P5) High binding affinity, to prevent escape of lymphocytes from lymph nodes, reducing the number of peripheral blood lymphocytesResearch shows that Sydney Maude piece can prevent neurodegeneration occurs synapses and promote CNS remyelinationIt has the potential to change the course of the diseaseIt is reported that in March 2019, January 2020, Sydney Maude has won the United States, the European Union approved for marketingAccording to Novartis, the drug product intellectual data registered in February 2019 to declare the domestic market, was subsequently incorporated into the priority review process, which lasted 15 months, quickly approved the listing provides a new treatment option for patients with relapsing forms of multiple sclerosis, to better meet the clinical needs of patientsmultiple sclerosis (MS) is a chronic inflammatory autoimmune diseases, the etiology of the patient's own immune system attacks the myelin nerve protection, resulting in the exchange of information with other parts of the body of the brain is blocked, the MS major clinical course is divided into primary progressive multiple sclerosis (PPMS), relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), 85% belong to multiple sclerosis, relapsing-remitting multiple sclerosisIf not effectively treated, RRMS patients will progress 50% -60% of SPMSAccording to incomplete statistics, there are MS patients worldwide about 2.3 million, of which 3% -5% were children or teenagers; China's MS prevalence rate is about 7.5 / 100,000, about 30,000 more than the patientMay 2018, China will multiple sclerosis (MS) as part of China, "the first batch of rare diseases directory."present, including Sydney, including Maude, the global total of 4 oral MS drugs on the market, and the remaining three are Novartis' fingolimod, Sanofi's teriflunomide and Biogen rich horse dimethyl Sydney Maudeis worth mentioning that in July 2019, Novartis has fingolimod in relapsing multiple sclerosis (RMS) in China approved for the treatment of 10-year-old or 10-year-old patientFingolimod is the only indication of a children's disease, multiple sclerosis correction therapy (DMT) drugsThe Sydney Maude is the first to be verified has a unique effect in SPMS patients DMT oral medicationUp to now, the domestic market hardening treatment of relapsing forms of oral pharmaceutical total of three models, Sanofi are declared teriflunomide sheet (Teriflunomide, trade name: Obama Czech Republic) and hydrochloric acid Novartis declared Fen Ge Mode capsules, tablets and the Sydney Maude approvedEditor: thirty-seven Disclaimer: This article is finishing for the opinions of the authors and do not represent the position of drug intellectual network, please share in the comments section to add; For reprint, please be sure to specify the article author and sources Related Tags: a country, a Novartis, Sydney Maude 0 0 < br />